Literature DB >> 11858629

Quinolones: a comprehensive review.

Catherine M Oliphant1, Gary M Green.   

Abstract

With the recent introduction of agents such as gatifloxacin and moxifloxacin, the traditional gram-negative coverage of fluoroquinolones has been expanded to include specific gram-positive organisms. Clinical applications beyond genitourinary tract infections include upper and lower respiratory infections, gastrointestinal infections, gynecologic infections, sexually transmitted diseases, and some skin and soft tissue infections. Most quinolones have excellent oral bioavailability, with serum drug concentrations equivalent to intravenous administration. Quinolones have few adverse effects, most notably nausea, headache, dizziness, and confusion. Less common but more serious adverse events include prolongation of the corrected QT interval, phototoxicity, liver enzyme abnormalities, arthropathy, and cartilage and tendon abnormalities. The new fluoroquinolones are rarely first-line agents and should be employed judiciously. Inappropriate use of agents from this important class of antibiotics will likely worsen current problems with antibiotic resistance. Applications of fluoroquinolones in biologic warfare are also discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858629

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  102 in total

1.  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Authors:  Matthew G Blango; Matthew A Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

2.  Ofloxacin induced hypomania.

Authors:  Siddharth Sarkar; Sudhir Kumar Khandelwal
Journal:  J Clin Diagn Res       Date:  2013-07-01

3.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

4.  [Modification of the histopathologic degree of inflammation in asymptomatic prostatitis (NIH IV) by moxifloxacin].

Authors:  T Bschleipfer; F M E Wagenlehner; W Weidner
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

5.  Influence of type and neutralisation capacity of antacids on dissolution rate of ciprofloxacin and moxifloxacin from tablets.

Authors:  Alija Uzunović; Edina Vranić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

6.  Implementation of daily chlorhexidine bathing to reduce colonization by multidrug-resistant organisms in a critical care unit.

Authors:  Jackson S Musuuza; Ajay K Sethi; Tonya J Roberts; Nasia Safdar
Journal:  Am J Infect Control       Date:  2017-04-18       Impact factor: 2.918

7.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

8.  Polymer-Based Bioorthogonal Nanocatalysts for the Treatment of Bacterial Biofilms.

Authors:  Rui Huang; Cheng-Hsuan Li; Roberto Cao-Milán; Luke D He; Jessa Marie Makabenta; Xianzhi Zhang; Erlei Yu; Vincent M Rotello
Journal:  J Am Chem Soc       Date:  2020-06-08       Impact factor: 15.419

9.  Factor analysis of microbiological activity data and structural parameters of antibacterial quinolones.

Authors:  Marcin Koba; Tomasz Baczek; Katarzyna Macur; Leszek Bober; Teresa Frackowiak; Adam Buciński; Danuta Rystok-Grabska; Jolanta Stasiak; Katarzyna Koba
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

10.  P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; Thomas Harnois; Alain Kitzis; Jean-Christophe Olivier; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.